Skip to main content

Table 4 Patients with improved quality of life – EQ-5D-3 L questionnaire (longitudinal population)

From: Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study

Parameter Baseline (N = 121) 6 months
(N = 113)
12 months
(N = 103)
No problems in walking 47.9 73.5 72.8
No problems in self-care 74.4 91.2 90.3
No problems in performing usual activitiesa 36.7 58.4 65.0
No pain/discomfortb 31.4 61.9 63.7
No anxiety/depression 34.7 57.5 57.3
VAS scores, mean ± SD 55.1 ± 18.4 69.2 ± 15.9 71.0 ± 16.0
  1. Data are presented as % of patients, unless otherwise specified
  2. aN = 120 at baseline; bN = 102 at 12 months
  3. P < 0.0001 for VAS score changes from baseline to 6 months as well as 12 months. P-value was calculated using paired t-test
  4. EQ-5D-3 L EuroQoL five-dimensional three-level questionnaire, SD standard deviation, VAS Visual Analogue Scale